Session

Metastatic prostate cancer

ESU Course 48

  • Location:
    Room 12 (ICM, Level 1)
  • Chair:
     K. Pummer, Graz (AT)
  • Aims and objectives of this session

    The three lectures of ESU course 48 will provide comprehensive state-of-the-art information about currently available therapies for hormone-naïve and castration resistant prostate cancer, such as various forms of primary androgen deprivation, immunotherapy, chemotherapy, and therapies approved for CRPC. After the course, attendees should be able to adequately treat patients with metastatic prostate cancer at all disease stages.

First and second line hormonal therapy: What should be considered?
 K. Miller, Berlin (DE)
What is the role of chemotherapy and immunotherapy in patients with CRPC?
 G. Mickisch, Bremen (DE)
New therapeutic options for patients with CRPC – more possibilities, more questions?
 K. Pummer, Graz (AT)
Case discussion
 G. Mickisch, Bremen (DE)
 
 K. Miller, Berlin (DE)
 
 K. Pummer, Graz (AT)